Literature DB >> 20175817

Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.

M Gazouli1, I Pachoula, I Panayotou, G Mantzaris, V P Syriopoulou, N Goutas, D Vlachodimitropoulos, N P Anagnou, E Roma-Giannikou.   

Abstract

BACKGROUND AND
OBJECTIVE: Azathioprine (AZA) and 6-mercaptopurine (6MP) are used in the treatment of paediatric inflammatory bowel disease (IBD). Genetic variations in thiopurine S-methyltranfarase (TPMT) gene have been correlated with enzyme activity and with the occurrence of adverse events to AZA and 6MP. The aim of the present study was to investigate the frequency of the functional TPMT polymorphisms and their association with the occurrence of adverse events during azathioprine therapy in a paediatric IBD cohort.
METHODS: Ninety-seven thiopurine-treated paediatric IBD patients (41.24% boys and 58.76% girls) with a mean age 11.25 years (range 3-16), were assessed for TPMT polymorphisms and adverse events.
RESULTS: Of the 97 patients enrolled in the study, 18 (18.56%) were heterozygous mutated; two (2.06%) were homozygous for a mutated TPMT gene. Ten patients (10.31%) developed adverse effects, and four of them (40%) had one of the variant alleles.
CONCLUSIONS: In this small cohort of subjects, no association was found between TPMT polymorphisms and the occurrence of thiopurines-related adverse events.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175817     DOI: 10.1111/j.1365-2710.2009.01041.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  6 in total

1.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

2.  Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease.

Authors:  Muaria Gazouli; Ioanna Pachoula; Ioanna Panayotou; Georgios Chouliaras; Nicholas P Anagnou; George Chroussos; Eleftheria Roma
Journal:  Ann Gastroenterol       Date:  2012

Review 3.  Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Authors:  Vid Mlakar; Patricia Huezo-Diaz Curtis; Chakradhara Rao Satyanarayana Uppugunduri; Maja Krajinovic; Marc Ansari
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

4.  Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease.

Authors:  Hong-Hui Wang; Ying He; Hong-Xian Wang; Cheng-Ling Liao; Yu Peng; Li-Jian Tao; Wei Zhang; Hui-Xiang Yang
Journal:  World J Gastroenterol       Date:  2018-02-28       Impact factor: 5.742

5.  Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis.

Authors:  Yulan Liu; Yang Meng; Lu Wang; Zhou Liu; Jiao Li; Weiguo Dong
Journal:  Onco Targets Ther       Date:  2018-11-23       Impact factor: 4.147

Review 6.  Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.

Authors:  Anastasia Konidari; Antonios Anagnostopoulos; Laura J Bonnett; Munir Pirmohamed; Wael El-Matary
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.